What is the recommended bupivacaine infusion rate per kilogram of body weight for epidural analgesia?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 25, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Recommended Bupivacaine Infusion Rate for Epidural Analgesia

For epidural bupivacaine infusions, use 0.1 mg/kg/hour (equivalent to 0.4 mL/kg/hour of 0.25% bupivacaine) in adults, with lower doses required in pediatric patients based on age-specific pharmacokinetics.

Adult Dosing

The FDA-approved labeling for bupivacaine does not specify a single per-kilogram infusion rate, instead emphasizing individualized dosing with maximum daily limits of 400 mg over 24 hours 1. However, research evidence demonstrates that 0.1 mg/kg/hour provides effective epidural analgesia when combined with adjuvants 2.

Key considerations for adult epidural infusions:

  • Administer in incremental doses of 3-5 mL with sufficient time between doses to detect intravascular or intrathecal injection 1
  • Use 0.25% or 0.5% concentrations for epidural analgesia (0.75% is contraindicated in obstetrics) 1
  • Maximum single dose should not exceed 175 mg without epinephrine or 225 mg with epinephrine 1:200,000 1
  • Doses may be repeated every 3 hours, but total daily dose should not exceed 400 mg 1

Pediatric Dosing

Bupivacaine is NOT recommended for continuous epidural infusion in pediatric patients under 12 years according to FDA labeling 1. The 2025 pediatric regional anesthesia guidelines strongly favor ropivacaine over bupivacaine for pediatric epidural infusions due to lower systemic toxicity and reduced motor blockade 3.

If ropivacaine is used instead (the preferred agent):

  • Infants ≤180 days (≤6 months): 0.2 mL/kg/hour of 0.2% ropivacaine
  • Children >180 days (>6 months): 0.4 mL/kg/hour of 0.2% ropivacaine 3

Critical Pediatric Safety Concern

Research demonstrates that even when total bupivacaine plasma concentrations appear acceptable (<1.5 mcg/mL), free bupivacaine concentrations are significantly higher in infants and can cause toxicity 4. Four of seven infants in one study showed adverse reactions despite "acceptable" total plasma levels, indicating that standard dosing recommendations may underestimate toxicity risk in young patients 4.

Practical Algorithm

For adults:

  1. Start with 0.1 mg/kg/hour (use 0.25% bupivacaine = 0.4 mL/kg/hour)
  2. Reduce dose by 30-50% in elderly, debilitated, or patients with cardiac/hepatic disease 1
  3. Always use test dose with epinephrine (10-15 mcg) before full dose 1
  4. Monitor total daily dose to stay under 400 mg/24 hours 1

For pediatric patients:

  1. Switch to ropivacaine - bupivacaine is not recommended under age 12 1
  2. If ropivacaine unavailable and bupivacaine must be used, reduce doses substantially below adult recommendations
  3. In infants, use the lowest possible doses and monitor closely for CNS toxicity signs 4

Common Pitfalls

  • Measuring only total bupivacaine levels in infants - Free drug concentrations are what cause toxicity, and these are disproportionately elevated in young patients 4
  • Rapid bolus injection - Always use fractional, incremental dosing with frequent aspiration 1
  • Skipping test doses - Even with negative aspiration, intravascular injection remains possible 1
  • Using 0.75% concentration in obstetrics - This is explicitly contraindicated 1

The evidence strongly supports ropivacaine as the superior choice for pediatric epidural analgesia, with bupivacaine reserved primarily for adult patients 3.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.